Estie Mermelstein, MSN, FNP-BC

Estie Mermelstein, MSN, FNP-BC, earned her Master of Science in nursing from Columbia University School of Nursing. She has worked as a nurse in women’s health and as a nurse practitioner in family medicine. Estie also earned a Bachelor of Arts in journalism and was editor-in-chief of her undergraduate newspaper. She currently freelances in medical communications with a focus on clinician-facing content. She and her husband have three young children and live in New Jersey.

All articles by Estie Mermelstein, MSN, FNP-BC

A doctor takes measurements of an overweight patient.

HIV/AIDS

Impact of Diet Among Patients With HIV at Risk for Antiretroviral Therapy-Associated Weight Gain

Estie Mermelstein, MSN, FNP-BC

October 14, 2021

Investigators conducted a study to determine the effects of antiretroviral therapy on weight gain in patients with HIV infection.

HIV/AIDS

Efficacy of First-Line Treatment With Dolutegravir/Lamivudine in Patients With Newly Diagnosed HIV Infection

Estie Mermelstein, MSN, FNP-BC

October 13, 2021

Investigators conducted a secondary analysis that assessed virologic outcomes following 48 weeks of first-line treatment with dolutegravir/lamivudine in patients with newly diagnosed HIV infection.

ID Week 2021

Optimal Time Identified for Monoclonal Antibody Infusions in Patients With COVID-19

Estie Mermelstein, MSN, FNP-BC

October 1, 2021

Researchers sough to assess the effects of treatment with a monoclonal antibody infusion in patients hospitalized with COVID-19.

ID Week 2021

Safety, Tolerability, Immunogenicity of the Novel Pneumococcal Conjugate Vaccine V114 in Patients at Risk for Pneumococcal Disease

Estie Mermelstein, MSN, FNP-BC

October 1, 2021

Researchers sought to assess the safety, tolerability, and immunogenicity of a novel pneumococcal conjugate vaccine (V114) in patients at risk for pneumococcal disease.

COVID19

Seroconversion Rates Post SARS-CoV-2 Vaccination in Patients With Immune-Mediated Inflammatory Diseases

Estie Mermelstein, MSN, FNP-BC

September 27, 2021

Investigators conducted a systemic review to assess the effects of various medications on seroconversion rates following SARS-CoV-2 vaccination in patients with immune mediated inflammatory disease.

Nosocomial Infections

Incidence of Septic Shock in Patients With Chronic Liver Disease Admitted to the Intensive Care Unit for Treatment of Candidemia

Estie Mermelstein, MSN, FNP-BC

September 23, 2021

Investigators sought to identify factors associated with septic shock development and 30-day mortality in patients admitted to an intensive care unit for treatment of candidemia.

Nosocomial Infections

Outcomes of Empiric Antibiotic Therapy With Adjunctive Gentamicin in Patients With Septic Shock

Estie Mermelstein, MSN, FNP-BC

September 23, 2021

Investigators conducted a study to determine whether empiric antibiotic therapy with adjunctive gentamicin improves outcomes in patients with septic shock admitted to the intensive care unit.

COVID19

Outcomes of Patients With COVID-19 Infected With a Variant of Concern: Alpha, Beta, Delta

Estie Mermelstein, MSN, FNP-BC

September 22, 2021

Investigators conducted a study that compared outcomes between patients with COVID-19 infected with the Alpha, Beta, or Delta variants and those infected with wild-type virus.

General Medicine

Are Higher Neuraminidase Antibody Concentrations Associated With Decreased Disease Severity in Individuals With Influenza?

Estie Mermelstein, MSN, FNP-BC

September 21, 2021

Immunity against neuraminidase is important to consider in development of therapeutics and influenza vaccines with improved efficacy and protection.

COVID19

Clinical Efficacy, Safety of Janus Kinase Inhibitors in Patients Hospitalized With COVID-19

Estie Mermelstein, MSN, FNP-BC

September 10, 2021

Investigators conducted a meta-analysis of 3 randomized controlled trials that compared the clinical safety and efficacy of janus kinase inhibitors with placebo or standard care for the treatment of patients with COVID-19.

Next post in COVID19